Tarsus Pharmaceuticals, Inc. financial data

Symbol
TARS on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
15440 Laguna Canyon Road, Irvine, California
State of incorporation
Delaware
Fiscal year end
December 31
Latest financial report
10-Q - Q2 2024 - Aug 8, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 790 % -46.5%
Quick Ratio 6.06 %
Debt-to-equity 34.3 % +66.3%
Return On Equity -64 % -26%
Return On Assets -47.6 % -13.2%
Operating Margin -188 % +75.5%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 38M shares +16.6%
Common Stock, Shares, Outstanding 38M shares +41.4%
Entity Public Float 460M USD +155%
Common Stock, Value, Issued 6K USD +20%
Weighted Average Number of Shares Outstanding, Basic 37.8M shares +41%
Weighted Average Number of Shares Outstanding, Diluted 37.8M shares +41%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 83.4M USD +567%
Research and Development Expense 49.8M USD +8.62%
General and Administrative Expense 58.8M USD +190%
Costs and Expenses 74.1M USD +126%
Operating Income (Loss) -156M USD -63.3%
Nonoperating Income (Expense) 6.3M USD +31.7%
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent -150M USD -65%
Earnings Per Share, Basic -4.46 USD/shares -33.1%
Earnings Per Share, Diluted -4.46 USD/shares -33.1%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 181M USD +69.6%
Marketable Securities, Current 142M USD +99.4%
Accounts Receivable, after Allowance for Credit Loss, Current 29.5M USD
Inventory, Net 2.2M USD
Assets, Current 363M USD +97.6%
Property, Plant and Equipment, Net 2.24M USD +45.4%
Operating Lease, Right-of-Use Asset 1.97M USD -7.86%
Intangible Assets, Net (Excluding Goodwill) 3.67M USD
Other Assets, Noncurrent 846K USD -41.7%
Assets 377M USD +99.5%
Employee-related Liabilities, Current 8.05M USD +51.6%
Contract with Customer, Liability, Current 0 USD -100%
Liabilities, Current 51.6M USD +249%
Operating Lease, Liability, Noncurrent 1.45M USD -20.2%
Other Liabilities, Noncurrent 1.45M USD -20.6%
Liabilities 125M USD +202%
Accumulated Other Comprehensive Income (Loss), Net of Tax -176K USD -665%
Retained Earnings (Accumulated Deficit) -314M USD -91.7%
Stockholders' Equity Attributable to Parent 252M USD +70.7%
Liabilities and Equity 377M USD +99.5%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -37.8M USD -72%
Net Cash Provided by (Used in) Financing Activities 109M USD +2070%
Net Cash Provided by (Used in) Investing Activities -102M USD -1005%
Common Stock, Shares Authorized 200M shares 0%
Common Stock, Shares, Issued 38M shares +41.4%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -31.2M USD -452%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 181M USD +69.6%
Interest Paid, Excluding Capitalized Interest, Operating Activities 868K USD +46.4%
Deferred Tax Assets, Valuation Allowance 60.3M USD +139%
Deferred Tax Assets, Gross 61M USD +141%
Operating Lease, Liability 2.05M USD -8.55%
Depreciation 710K USD +65.5%
Payments to Acquire Property, Plant, and Equipment 174K USD -48.8%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -150M USD -65.1%
Lessee, Operating Lease, Liability, to be Paid 2.51M USD -10.8%
Property, Plant and Equipment, Gross 3.84M USD +61.8%
Operating Lease, Liability, Current 605K USD +40.4%
Lessee, Operating Lease, Liability, to be Paid, Year Two 994K USD +26%
Lessee, Operating Lease, Liability, to be Paid, Year One 961K USD +37.1%
Operating Lease, Weighted Average Discount Rate, Percent 0.1 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 288K USD -33.6%
Lessee, Operating Lease, Liability, to be Paid, Year Three 83K USD -89.8%
Deferred Tax Assets, Operating Loss Carryforwards 25.9M USD +287%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 3.93M USD +15.8%
Lessee, Operating Lease, Liability, to be Paid, Year Four 0 USD -100%
Additional Paid in Capital 566M USD +81.8%
Preferred Stock, Shares Outstanding 0 shares
Amortization of Intangible Assets 100K USD
Deferred Tax Assets, Net of Valuation Allowance 733K USD +496%
Share-based Payment Arrangement, Expense 23.7M USD +45.1%
Interest Expense 3.65M USD +42%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%